Oral Micronized Progesterone Compassionate Use and Expanded Access

What "Compassionate Use" and "Expanded Access" Actually Mean for Progesterone

Compassionate use and expanded access are FDA mechanisms that let patients outside a clinical trial obtain an unapproved or investigational drug when no comparable alternative exists. Oral micronized progesterone does not qualify for either pathway because it has been FDA-approved since 1998 and is sold commercially as both a brand (Prometrium) and multiple generics.

The FDA describes expanded access as appropriate only "when there is no comparable or satisfactory alternative therapy available to diagnose, monitor, or treat the patient's disease or condition" (FDA Expanded Access guidance). Because generic micronized progesterone is readily purchasable at retail pharmacies nationwide, that threshold is not met.

What patients searching for "compassionate use" of oral micronized progesterone usually need is cost relief, not a regulatory workaround. The sections below cover every practical cost-reduction pathway available in 2026.

Why Patients Confuse Affordability Problems with Compassionate Use

The confusion is understandable. Patients who cannot afford a prescribed medication sometimes hear "compassionate use" as a phrase meaning "getting a drug when normal channels fail." The clinical definition is narrower. Cost barriers are addressed through patient assistance programs (PAPs), generic substitution, discount cards, and insurance appeals, not through the FDA's expanded-access office.

When Oral Progesterone Might Involve a Formal Access Issue

One narrow scenario does involve access complexity: compounded bioidentical progesterone. The FDA has raised concerns about compounded hormone preparations when a commercially available FDA-approved product like Prometrium exists (FDA statement on compounded menopause hormones). Patients seeking a specific dose or formulation not commercially available may work with a 503A compounding pharmacy, but this is a compounding question, not an expanded-access question.

The Clinical Case for Oral Micronized Progesterone

Oral micronized progesterone is the preferred progestogen for most women on menopausal hormone therapy based on its safety profile relative to synthetic progestins.

The Women's Health Initiative (WHI), which used medroxyprogesterone acetate (MPA), not micronized progesterone, reported a small but statistically significant increase in breast cancer incidence with combined estrogen-progestin therapy over 5.6 years [1]. Subsequent observational data suggest micronized progesterone carries a lower breast cancer signal than MPA, though randomized head-to-head trials are lacking [2].

The KEEPS Trial and Cardiovascular Data

The Kronos Early Estrogen Prevention Study (KEEPS, N=727) assigned recently menopausal women to oral conjugated equine estrogen plus oral progesterone 200 mg for 12 days per cycle, transdermal estradiol plus the same progesterone regimen, or placebo over 4 years. Neither active arm produced the carotid-intima-media-thickness changes seen in WHI, and the oral progesterone arm showed no significant increase in venous thromboembolism versus placebo [3].

The E3N Cohort and Breast Cancer Risk

The French E3N cohort (N=80,377 postmenopausal women) found that women using estrogen combined with micronized progesterone had a relative risk of breast cancer of 1.00 (95% CI 0.83 to 1.22) compared with non-users, whereas estrogen plus synthetic progestins carried a relative risk of 1.69 (95% CI 1.50 to 1.91) [2]. That single datum has driven substantial guideline shifts toward preferring micronized progesterone.

Endometrial Protection: The Primary FDA Indication

The FDA approved oral micronized progesterone 200 mg daily for 12 days per 28-day cycle specifically to prevent endometrial hyperplasia in postmenopausal women taking conjugated estrogens. The key trial submitted for approval showed statistically significant endometrial protection versus estrogen alone (P<0.001) [4]. Continuous daily dosing at 100 mg is an off-label but widely used approach, and the 2022 Menopause Society (formerly NAMS) position statement supports both regimens [5].

Generic Oral Micronized Progesterone: The First Cost-Reduction Step

Generic micronized progesterone 100 mg and 200 mg capsules are manufactured by multiple companies, including Actavis (now Allergan/AbbVie), Perrigo, and Teva. They carry the same FDA-approved labeling as Prometrium and use the same peanut-oil suspension vehicle.

Average retail cash prices in 2026:

| Formulation | Brand (Prometrium) | Generic (avg.) | With GoodRx discount | |---|---|---|---| | 100 mg, 30 capsules | $65, $85 | $30, $55 | $15, $35 | | 200 mg, 30 capsules | $95, $130 | $50, $75 | $25, $50 |

Prices vary by pharmacy. Costco and Walmart pharmacies typically price generics 20 to 35% below chain drugstore cash prices.

Requesting Generic Substitution

Ask your prescriber to write "DAW-0" (dispense as written is not required) or simply "generic acceptable" on the prescription. Most state laws allow pharmacists to substitute an FDA-approved generic automatically unless the prescriber specifies otherwise.

Bioequivalence and Substitution Safety

FDA requires generic oral progesterone to demonstrate bioequivalence, specifically, that the 90% confidence interval for the AUC and Cmax ratios falls within 80 to 125% of the reference listed drug [6]. All currently marketed generics have passed this standard.

Discount Cards and Coupon Programs

Discount cards work at the pharmacy counter for patients paying cash (not using insurance). They cannot be combined with Medicare, Medicaid, or most federal insurance programs, per federal anti-kickback rules.

GoodRx, SingleCare, and RxSaver

GoodRx reports cash prices as low as $18 for 30 capsules of generic progesterone 100 mg at certain pharmacies (verified January 2026). SingleCare and RxSaver often show slightly different contracted rates at the same chain. Comparing all three before filling is worth 2 to 3 minutes of time and can save $10, $20 per fill.

Mark Cuban's Cost Plus Drugs

Cost Plus Drugs (costplusdrugs.com) sells generic progesterone 100 mg at a transparent cost-plus-15% markup. As of late 2025, the price was approximately $14 for 30 capsules with a $5 dispensing fee, totaling roughly $19 delivered by mail. The pharmacy requires a valid prescription and ships to most US states.

Patient Assistance Programs (PAPs) for Oral Progesterone

Because generics are so inexpensive, formal PAPs for oral progesterone are less critical than for specialty drugs costing thousands per month. Still, several pathways exist for patients who remain cost-burdened.

Solvay / Abbott Legacy Program

Solvay Pharmaceuticals (now part of the AbbVie portfolio after multiple acquisitions) historically offered a patient assistance program for Prometrium brand. In 2026, brand Prometrium access support is managed through AbbVie's myAbbVie Assist program. Income thresholds and residency requirements change annually; patients should verify current eligibility at needymeds.org or rxassist.org rather than relying on cached web information.

NeedyMeds and RxAssist Databases

NeedyMeds (needymeds.org) and RxAssist (rxassist.org) maintain updated PAP databases searchable by drug name. Both list income limits, application procedures, and phone numbers for generic progesterone programs from individual manufacturers. These databases are free to use and are updated quarterly.

State Pharmaceutical Assistance Programs (SPAPs)

Approximately 24 states operate SPAPs that help residents with drug costs outside Medicare Part D. New Jersey's PAAD program, Pennsylvania's PACE program, and New York's EPIC program each cover progesterone for income-qualifying seniors. Eligibility and formulary inclusion vary by state and year.

Insurance Coverage: Appeals, Prior Authorization, and Step Therapy

Most commercial insurance plans cover generic oral progesterone with a Tier 1 or Tier 2 copay, typically $5, $25 per month. Medicare Part D coverage depends on the specific plan formulary.

Prior Authorization for Brand Prometrium

If a prescriber determines brand Prometrium is medically necessary (for example, a patient with documented adverse reaction to a specific generic excipient), the insurer may require prior authorization. The appeal should document:

1. The specific clinical reason brand is required.
2. Failure of or contraindication to generic.
3. Supporting literature if the generic excipient causes a documented reaction.

Step Therapy Waivers

Some states have enacted step-therapy override laws that allow prescribers to bypass insurer-mandated step therapy requirements when a specific agent is clinically indicated. The National Alliance of Mental Illness (NAMI) maintains a state-by-state step therapy law tracker, useful when progesterone is prescribed off-label for premenstrual dysphoric disorder (PMDD) or sleep.

HSA and FSA Eligibility for Oral Micronized Progesterone

Yes. Oral micronized progesterone purchased with a valid prescription from a licensed clinician is an HSA- and FSA-eligible expense under IRS Publication 502, which defines eligible medical expenses to include "prescribed medicines and drugs."

The CARES Act (2020) expanded over-the-counter medication eligibility but did not change the rule for prescription drugs: any FDA-approved drug with a valid prescription qualifies [7]. Progesterone is prescription-only in the United States, so every prescription fill is fully reimbursable from an HSA or FSA account.

Practical Steps to Use HSA/FSA

Pay at the pharmacy counter with your HSA debit card directly, or pay out of pocket and submit the pharmacy receipt for FSA reimbursement. Keep the prescription label (which includes the prescriber's name, drug name, and date) as documentation. Over-the-counter progesterone creams sold without a prescription do not qualify.

FSA Deadline Reminder

FSA funds generally follow a "use it or lose it" calendar-year rule (with some plans offering a $610 rollover limit in 2026 or a 2.5-month grace period). Scheduling refills before December 31 avoids forfeiting unused FSA dollars.

Telehealth Prescribing and Cost Transparency

Telehealth platforms have reduced the prescribing friction for hormone therapy substantially. A clinician at a telehealth practice can evaluate a patient's indication, order labs, and send a prescription to any retail or mail-order pharmacy in the same visit.

The practical cost advantage: telehealth visits for hormone therapy often run $75, $150 per consultation, compared with $200, $400 for an in-person specialist visit in many US markets. For a patient whose primary barrier is access to a prescriber (rural location, no local endocrinologist or OB-GYN), telehealth combined with Cost Plus Drugs or a GoodRx coupon at a local pharmacy can reduce total monthly cost to under $40.

What a Clinician Evaluates Before Prescribing

Before prescribing oral micronized progesterone, a clinician should confirm:

• Indication (endometrial protection with estrogen, amenorrhea, PMDD, sleep, luteal support in ART).
• Peanut allergy status (Prometrium and most generics use peanut oil; allergy is a contraindication per labeling) [4].
• Baseline endometrial status if postmenopausal uterine bleeding is present.
• Drug interactions, particularly with CYP3A4 inducers such as rifampin, which reduce progesterone exposure [4].

Compounded Progesterone: When and Why It Is Used

Some patients or clinicians prefer compounded micronized progesterone for doses not commercially available (for example, 50 mg capsules for sleep support or transdermal or vaginal formulations). The FDA has stated that when an FDA-approved product exists, the clinical rationale for compounding must be clear and patient-specific FDA compounding guidance.

Compounded progesterone is typically more expensive than generic oral capsules ($40, $90 per month for a compounded oral or vaginal preparation versus $15, $35 for a generic capsule). Insurance rarely covers compounded hormones. HSA/FSA funds can cover compounded prescriptions when accompanied by a valid prescription from a licensed practitioner.

The 2022 Menopause Society position statement notes: "Compounded hormone therapy should be reserved for situations in which an FDA-approved product cannot be used," citing lack of efficacy and safety data for compounded preparations [5].

The HealthRX Cost-Access Decision Framework for Oral Micronized Progesterone matches a patient's specific access barrier to the most efficient solution:

| Barrier | Best-fit solution | Expected monthly cost | |---|---|---| | No insurance | Generic + GoodRx or Cost Plus Drugs | $15, $35 | | High copay on brand | Request generic substitution (DAW-0) | $5, $25 copay | | Income below 200% FPL | NeedyMeds PAP search + state SPAP | $0, $10 | | No local prescriber | Telehealth consult + mail-order pharmacy | $40, $80 (first month) | | Peanut allergy | Compounded sesame-oil or olive-oil capsule | $40, $90 | | Need non-standard dose | 503A compounding pharmacy | $40, $90 |

Dosing Reference for Common Indications

The following doses reflect FDA labeling and published guideline recommendations. All off-label uses should be discussed with a licensed clinician.

Endometrial Protection (FDA-Approved)

200 mg orally at bedtime for 12 consecutive days per 28-day cycle, taken with conjugated estrogens [4]. This is the only fully FDA-approved dosing regimen in the product label.

Continuous Combined HRT (Off-Label but Guideline-Supported)

100 mg orally at bedtime nightly, used continuously with daily estrogen. The 2022 Menopause Society clinical practice guidelines describe this as an accepted approach with a favorable endometrial safety profile [5].

Luteal Phase Support in Assisted Reproductive Technology

200 to 400 mg vaginally or 200 mg orally three times daily, per ASRM practice guidelines for luteal support [8]. Insurance coverage for this indication varies.

Sleep and PMDD (Off-Label)

100 mg at bedtime. The sleep-promoting effect is attributed to progesterone's metabolite allopregnanolone acting on GABA-A receptors [9]. This indication is widely used but not FDA-labeled.

Safety Considerations That Affect Prescribing Access Decisions

A clinician may decline to prescribe or require additional evaluation before prescribing if any of the following are present:

• Undiagnosed vaginal bleeding.
• Known or suspected breast cancer or hormone-sensitive malignancy.
• Active thromboembolic disorder.
• Liver dysfunction (progesterone is extensively hepatically metabolized) [4].
• Documented peanut allergy (requires alternative formulation).

The USPSTF 2022 recommendation statement on menopausal hormone therapy for primary prevention of chronic conditions gives a "D" recommendation against use for that specific purpose, while acknowledging that use for symptom management is a separate clinical decision [10]. Patients using progesterone for symptom relief or endometrial protection are in a different clinical category than the USPSTF's primary prevention scope.

Key Takeaways for Patients and Prescribers

Oral micronized progesterone is not a drug that requires compassionate use or expanded access. It is commercially available, generically manufactured, and affordable with the right combination of strategies.

For a patient paying cash with no assistance, generic progesterone 100 mg at Cost Plus Drugs runs approximately $19 per month. For an insured patient on a standard commercial plan, the generic Tier 1 copay is typically $5, $15. HSA and FSA funds cover every prescription fill. Patients with income-based barriers should search NeedyMeds and contact their state's SPAP before concluding they cannot afford treatment.

Start with generic substitution. That single step eliminates most of the cost gap between Prometrium and an unaffordable bill.